Skip to main content

Table 1 Algorithm for management of elevated intraocular pressure

From: Ozurdex® (a slow-release dexamethasone implant) in proliferative vitreoretinopathy: study protocol for a randomised controlled trial

Intraocular pressure (mmHg) Treatment Follow-up
≤ 25 None As per protocol schedule
>25 but <30 Single topical ocular hypotensive Within 6 weeks*
≥ 30 but <35 Dual topical ocular hypotensive Within 6 weeks
≥ 35 Oral administration of acetazolamide 500 mg and dual therapy (recheck intraocular pressure within 2 hours) After 2 hours:
1. Intraocular pressure <35 mmHg – oral administration of Diamox 250 mg SR bd 5 days + dual topical therapy F/U 1 week
2. Intraocular pressure ≥35 mmHg – same day glaucoma service input and/or consultant VR input
  1. SR = slow release, bd = twice daily, F/U = follow up, VR = vitreoretinal.
  2. *If intraocular pressure has not responded to single therapy or only partially responded, then a substitute agent will be tried or an additional agent added, respectively.